Activity identification of chimeric anti-caspase-3 mRNA hammerhead ribozyme in vitro and in vivo

To study the expression activity of various vectors containing anti-caspase-3 ribozyme cassettesin vivo, and to further study the role of caspas-3 in the apoptotic pathway, we constructed anti-caspase-3 hammerhead ribozyme embedded into the human snRNA U6, and detected the activity of the ribozymein vitro andin vivo. Meanwhile we compared it with the self-cleaving hammerhead ribozymes that we previously studied, and with the general ribozyme, cloned into RNA polymerase II expression systems. The results showed that the three ribozymes, p1.5RZ107, pRZ107 and pU6RZ107 had the correct structure, and that they could cleave caspase-3 mRNA exactly to produce two fragments: 143nt/553nt. p1.5RZ107 has the highest cleavage efficiencyin vitro, almost 80%. However, the U6 chimeric ribozyme, pU6RZ107, has the highest cleavage activityin vivo, almost to 65%, though it has lower cleavage activityin vitro. The cleavage results demonstrated that the pU6RZ107, the U6 chimeric ribozyme, could more efficiently express and downregulate the level of caspase-3in vivo, and the ribozyme could provide an alternative approach to the research into the mechanism of apoptosis and human gene therapy also.     

Activity identification of chimeric anti-caspase-3 mRNA hammerhead ribozyme in vitro and in vivo

To study the expression activity of various vectors containing anti-caspase-3 ribozyme cassettes in vivo, and to further study the role of caspas-3 in the apoptotic pathway, we constructed anti-caspase-3 hammerhead ribozyme embedded into the human snRNA U6, and detected the activity of the ribozyme in vitro and in vivo. Meanwhile we compared it with the self-cleaving hammerhead ribozymes that we previously studied, and with the general ribozyme, cloned into RNA polymerase II expression systems. The results showed that the three ribozymes, p1.5RZ107, pRZ107 and pU6RZ107 had the correct structure, and that they could cleave cas-pase-3 mRNA exactly to produce two fragments: 143nt/553nt. p1.5RZ107 has the highest cleavage efficiency in vitro, almost 80%. However, the U6 chimeric ribozyme, pU6RZ107, has the highest cleavage activity in vivo, almost to 65%, though it has lower cleavage activity in vitro. The cleavage results demonstrated that the pU6RZ107, the U6 chimeric ribozyme, could more efficiently expre     

慢性乙型肝炎的基因治疗研究

近年来 ,慢性乙型肝炎的治疗 (主要是抗病毒治疗 )已取得较大进展。尤其是α 干扰素 (ＩＦＮ α)的合理应用及核苷类似物药物的开发与应用 ,对慢性乙型肝炎的治疗有了较大进步 ,但其疗效还不理想。如ＩＦＮ α在有选择的病例中对乙肝的长期疗效仅为 30 %～ 40 %。新近开发的抗病毒药物核苷类似物如拉咪呋啶 (ｌａｍｉｖｕｄｉｎｅ)及华米可维 (ｆａｍｉ ｃｌｏｖｉｒ)等 ,也由于其抗病毒作用短暂及易于诱发ＤＮＡ多聚酶的突变而形成耐药性和停药后易于复发等缺点 ,使其应用受到一定限制。因此 ,抗乙肝病毒的基因治疗被寄于新的希望。本文就…     

U6嵌合型抗caspase-3核酶的体外及体内活性鉴定

为探讨caspase-3基因在细胞凋亡中的作用,及不同表达核酶的载体在体内的表达效果,本研究对比了3种表达核酶的真核质粒,包括RNA聚合酶Ⅱ启动的p1.5RZ107(自我剪切)和pRZ107及RNA聚合酶Ⅲ启动的嵌合于U6中的pU6RZ107在体外和在肝细胞BRL-3A内的活性,以期获得细胞内切割活性较高的的核酶载体方面的信息.结果显示,具有自我剪切功能的质粒p1.5RZ107在体外切割靶RNA的效率最高,几达80%;而体内caspase-3在RNA,蛋白水平及蛋白功能活性上均显著下降,证明核酶在体内均可有效地表达并切割底物,以pU6RZ107切割效率最高,约达65%,pRZ107次之,p1.5RZ107最低.结果表明,U6嵌合型核酶pU6RZ107体内可有效地表达核酶及下调靶RNA水平,这不仅为探讨caspase-3在凋亡途径中的作用,也可为今后的基因治疗提供研究基础.